Beximco Pharmaceuticals Statistics
Total Valuation
Beximco Pharmaceuticals has a market cap or net worth of GBP 215.61 million. The enterprise value is 277.46 million.
Market Cap | 215.61M |
Enterprise Value | 277.46M |
Important Dates
The next estimated earnings date is Monday, November 4, 2024.
Earnings Date | Nov 4, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Shares Outstanding | n/a |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 297.32M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.31 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.53, with an EV/FCF ratio of 6.09.
EV / Earnings | 7.24 |
EV / Sales | 1.00 |
EV / EBITDA | 4.53 |
EV / EBIT | 5.57 |
EV / FCF | 6.09 |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 14.73.
Current Ratio | 1.80 |
Quick Ratio | 0.45 |
Debt / Equity | 14.73 |
Debt / EBITDA | 0.78 |
Debt / FCF | 1.17 |
Interest Coverage | 6.82 |
Financial Efficiency
Return on equity (ROE) is 10.99% and return on invested capital (ROIC) is 8.37%.
Return on Equity (ROE) | 10.99% |
Return on Assets (ROA) | 6.97% |
Return on Capital (ROIC) | 8.37% |
Revenue Per Employee | 54,353 |
Profits Per Employee | 6,725 |
Employee Count | 5,700 |
Asset Turnover | 0.62 |
Inventory Turnover | 1.77 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.20% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -43.20% |
50-Day Moving Average | 33.75 |
200-Day Moving Average | 37.75 |
Relative Strength Index (RSI) | 15.19 |
Average Volume (20 Days) | 417,779 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Beximco Pharmaceuticals had revenue of GBP 309.81 million and earned 38.33 million in profits. Earnings per share was 0.09.
Revenue | 309.81M |
Gross Profit | 133.95M |
Operating Income | 55.76M |
Pretax Income | 49.78M |
Net Income | 38.33M |
EBITDA | 67.87M |
EBIT | 55.76M |
Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 12.45 million in cash and 53.41 million in debt, giving a net cash position of -40.96 million.
Cash & Cash Equivalents | 12.45M |
Total Debt | 53.41M |
Net Cash | -40.96M |
Net Cash Per Share | n/a |
Equity (Book Value) | 362.49M |
Book Value Per Share | 0.75 |
Working Capital | 69.55M |
Cash Flow
In the last 12 months, operating cash flow was 60.21 million and capital expenditures -14.64 million, giving a free cash flow of 45.57 million.
Operating Cash Flow | 60.21M |
Capital Expenditures | -14.64M |
Free Cash Flow | 45.57M |
FCF Per Share | n/a |
Margins
Gross margin is 43.24%, with operating and profit margins of 18.00% and 12.37%.
Gross Margin | 43.24% |
Operating Margin | 18.00% |
Pretax Margin | 16.07% |
Profit Margin | 12.37% |
EBITDA Margin | 21.91% |
EBIT Margin | 18.00% |
FCF Margin | 14.71% |
Dividends & Yields
Beximco Pharmaceuticals does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | -7.55% |
Years of Dividend Growth | n/a |
Payout Ratio | 29.69% |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 39.96% |
FCF Yield | n/a |
Stock Splits
The last stock split was on November 23, 2020. It was a forward split with a ratio of 1.1.
Last Split Date | Nov 23, 2020 |
Split Type | Forward |
Split Ratio | 1.1 |